- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Akụkọ
-
Akụkọ
Ọgwụgwọ 2A Ọgwụ Ọrịa cancer akpa ume 2026: Data ELCC ọhụrụ na ọgwụgwọ Neo-Adjuvant
Ọdịnaya Nghọta Ọdịnaya 2A Ọrịa Cancer Na-adịghị Obere Cell 2026 ELCC na-eme n'ime atụmatụ Neo-Adjuvant Strategies Ezubere Usoro ọgwụgwọ maka Ọkwọ ụgbọala-Mutated Stage 2A Ntụle Ntụle Ọrịa Cancer Ntụle nke Trea...
Ọgwụgwọ Ọrịa Cancer Indolent Indolent 2026: Protocol ọhụrụ maka nlanarị ogologo oge
Ọdịnaya Ịghọta Ọrịa Cancer Indolent Indolent na 2026 The Paradigm Shift: Site na ịwa ahụ ozugbo gaa na onyunyo na-arụ ọrụ nhọrọ ịwa ahụ pere mpe maka ọnya na-aga n'ihu na-apụta Ezubere T ...
Ọgwụgwọ Ọrịa Cancer na-adịghị arụ ọrụ nke ọma 2026: TIL ọhụrụ & Mmụpụta A kapịrị ọnụ.
Ọdịnaya The Paradigm Shift in Inoperable Lung Cancer Treatment Understanding Tumor-Infiltrating Lymphocyte (TIL) Therapy Bispecific Antibodies: The Dual-Target Approach Comparative Analysis of Eme...
Ọgwụgwọ ọrịa kansa akpa ume nke mbụ 2026: Ntuziaka ọhụrụ & Ọgwụgwọ Kacha ọhụrụ
Ọdịnaya Ịghọta Ọrịa cancer akpa ume nke mbụ na ụkpụrụ nchọpụta 2026 emelitere ntuziaka ọgwụgwọ maka ọganihu ọrịa kansa akpa ume na-abụghị nke obere cell na obere ọgwụgwọ ọrịa cancer akpa ume na-apụta ...
Ịwa Ọgwụgwọ Ọrịa Cancer akpa ume 2026: Ọhụrụ Neo-Adjuvant Breakthroughs
Ọdịnaya Evolution nke ịwa ahụ ọgwụgwọ ọrịa kansa akpa ume na 2026 Mmeri na Immunotherapy dabere na Neo-Adjuvant Regimens Therapy Ezubere maka usoro ịwa ahụ nke ndị ọrịa na-anya ọkwọ ụgbọ ala…
Nhọrọ ọgwụgwọ ọrịa cancer akpa ume obere cell 2026: ADC ọhụrụ & Immunotherapy Breakthroughs
Ọdịnaya Ịghọta Ọnọdụ Ọdịnihu dị ugbu a nke Nhọrọ Ọgwụgwọ Ọrịa Cancer Obere Cell nke Mbụ: Ngwakọta Immunotherapy The Rise of Antibody-Drug Conjugates (ADCs) Ezubere iche DLL3:...
